293results about How to "Improve lung function" patented technology

A method of managing a patient having an accumulation of mucoid, mucopurulent or purulent material containing glycosaminoglycans, the method comprising the step of administering at least one glycosaminoglycans degrading enzyme to the patient in an amount therapeutically effective to reduce at least one of the following: the visco-elasticity of the material, pathogens infectivity and inflammation. An article of manufacture comprising an inhaler including, as an active ingredient, at least one glycosaminoglycans degrading enzyme for generating aerosols including the enzyme for management a patient having an accumulation of mucoid, mucopurulent or purulent material containing glycosaminoglycans.

A method for treating Chronic Obstructive Pulmonary Disease (COPD) or chronic bronchitis to alleviate the discomforts of breathing by using non-thermal electroporation energy to ablate diseased portions of the lung including the bronchus, airways and alveoli which, in effect, opens the restrictive diseased portions thereby maximizing the overall surface area thereof causing improved airflow and uninhibited breathing.

The invention relates to dose escalation enzyme replacement therapy using acid sphingomyelinase (ASM) for the treatment of human subjects having acid sphingomyelinase deficiency (ASMD), and, in particular, patients with non-neurological manifestations of Niemann-Pick Disease (NPD), and in certain embodiments, NPD type B.

A method for treating glycogen storage disease by administering an effective amount of a composition that includes ketogenic odd carbon fatty acids that ameliorate the symptoms of these diseases.

There is provided the use of a methylxanthine derivative such as theophylline and a steroid in a synergistic combination for the treatment of chronic obstructive pulmonary disease, wherein the combination is administered by the inhaled route for pulmonary delivery.

The invention provides improved medical devices, therapeutic treatment systems, and treatment methods for treatment of the lung. A lung volume reduction system includes an implantable device having an elongate body that is sized and shaped for delivery via the airway system to a lung airway of a patient. The implant is inserted and positioned while the implant is in a delivery configuration, and is reconfigured to a deployed configuration so as to locally compress adjacent tissue of the lung, with portions of the elongate body generally moving laterally within the airway so as to laterally compress lung tissue. A plurality of such implants will often be used to treat a lung of a patient.

The invention relates to a device for controlling an air-condition sleep mode and a method for controlling the air-condition sleep mode by the device; the device at least comprises a controller for controlling the sleep mode, an indoor temperature sensor connected with a first input terminal of the controller, a compressor connected with a first output terminal of the controller and a blower system connected with a second output terminal of the controller; the invention is characterized by at least also comprising an indoor humidity sensor connected with a second input terminal of the controller and a humidifier connected with a third output terminal of the controller; the controller stores optimal humidity value scope of indoor air; the indoor air humidity actually measured by the indoor temperature sensor and the stored optimal humidity value scope of indoor air are compared to control the opening and closing of the humidifier. Compared with the prior art, the controller can not only carry out intelligent regulation and control on the temperature of the sleep mode but also utilize the humidifier to carry out the intelligent control on the indoor air humidity.

The invention discloses a traditional Chinese medicine compound medicament composition for treating asthma and a preparation method of the composition. The medicament composition is of a medicament prepared from the raw materials of 1-20 parts of Chinese angelica, 1-20 parts of thunberg fritillary bulb, 1-10 parts of lightyellow sophora root and1-10 parts of liquorice root in weight part according to a ratio. The invention further provides the preparation method of the medicament composition, namely the traditional Chinese medicine compound medicament composition, as well as a use thereof in medicaments for treating the asthma.

The invention discloses an Angelica keiskei wine brewing method. The Angelica keiskei wine brewing method comprises the following steps: 1, cleaning fresh grapes, draining, and beating to form a grape pulp; 2, filling the grape pulp into a container, and fermenting; 3, adding an Angelica keiskei material and white sugar after the fermentation is carried out for 2-3d, uniformly stirring to form a mixed pulp, and continuously fermenting for 30-40d to obtain an Angelica keiskei wine pulp; 4, filtering the Angelica keiskei wine pulp, and precipitating to obtain an Angelica keiskei wine; and 5, sealing the obtained Angelica keiskei wine for sale. The Angelica keiskei wine brewed through using the brewing method fully utilizes the nutrition of the Angelica keiskei and the grapes, contains abundant amino acids, has the efficacies of lung function improving, blood circulation reinforcing, blood pressure reducing, blood fat reducing, immunity improving, ageing preventing, digestion helping, fat reducing, appetite increasing, beauty treating, face caring and the like, and has the characteristics of simple method and less investment.

Methods and compositions to enhance mucus clearance and to treat of pulmonary lung disorders such as cystic fibrosis are disclosed. The methods utilize pulmonary surfactants, alone or combined with hyperosmotic agents, administered to patients in an amount effective to enhance mucus clearance. The compositions comprise a pulmonary surfactant combined with an osmotically active agent.

The invention relates to a Chinese medicinal composition for clearing heat, dispersing phlegm, ventilating the lung and relieving asthma and process for preparation, wherein the composition comprises Chinese ephedra, licorice root, bitter apricot seed, radish seeds, lepidium seed, purple perilla seed, baikal skullcap root, mulberry bark, clerodendroa cyrtophyllum, cordate houttuynia and gypsum.

A vest for a supine human has a one-piece cover with a front panel secured to a bladder coupled to a pulsator operable to subject the vest to repeated pulses of air which applies and releases pressure to the front of the thorax of a person. The bladder has an air chamber and a bottom transverse portion having an air receiving passage and openings to allow air to flow from the air receiving passage into the air chamber. A coil spring within the air receiving passage maintains the air receiving passage open to allow air and air pressure pulses to flow into the air chamber.

The present invention relates to methods and compositions for treating lymphangioleiomyomatosis in a human subject in need of such treatment. The methods comprise administering to the subject via inhalation an aerosol composition comprising rapamycin or a prodrug or derivative (including analog) thereof.

The present invention provides methods for treating pulmonary hypertension in a subject by delivering a therapeutic adeno-associated virus (AAV)-SERCA2 composition to a subject in need thereof.

The compound Chinese onion preparation for treating chronic obstructive lung disease is prepared with Chinese onion, trichosanthes peel, Chinese goldthread, immature bitter orange, cassia twig and other chinese medicine materials. The preparation process includes crushing material, ethanol extraction, depression recovery of ethanol, concentration, adding supplementary material, vacuum drying to obtain dry extract, crushing, and further steps to prepare tablet, capsule, drip pills and micro pills. The compound Chinese onion preparation has obvious functions of relieving cough, eliminating phlegm and relieving asthma, and may be used to treat chronic obstructive lung disease effectively. It is ideal medicine for COPD in acute stage and COPD in prolonged stage and chronic stage.

This invention is directed to substituted acylanilide compounds and uses thereof in treating muscular dystrophies such as Duchenne muscular dystrophy and Becker muscular dystrophy and in improving or preserving lung function and cardiac function in a subject suffering from Duchenne muscular dystrophy.

The invention discloses a lung-moistening biscuit with tea perfume and a processing method thereof. The lung-moistening biscuit with tea perfume is composed of the following materials in parts by weight: 30-50 parts of oat powder, 20-40 parts of common buckwheat, 200-300 parts of wheatmeal, 15-20 parts of snow pear, 8-15 parts of Phyllanthus emblica fruit, 10-15 parts of honey, 6-8 parts of lily root flour, 30-40 parts of lotus seed, 10-15 parts of agaric, 6-10 parts of spina date seed, 6-10 parts of yerba mate, 1-2 parts of mountain ash, 2-3 parts of lemon grass, 1-2 parts of radix asparagi, 1-2 parts of radix glehniae, 2-3 parts of purple bergenia herb, 1-2 parts of astilbe chinensis, 10-15 parts of nutrition additive and 8-15 parts of coix seed oil. The lung-moistening biscuit with tea perfume is integrated with unique fresh tea perfume, sweet and crisp, special in flavor, abundant and balanced in nutrition, applicable to all kinds of people, added with multiple traditional Chinese medicines and compatible with multiple food materials, has the effects on clearing away the lung heat, relieving cough, moistening the lung and strengthening the spleen and clearing away heat and reducing fire, and improves the lung function, thus being healthy.

A sea-buckthorn and milk vetch root beverage for preventing SARS, characterized in that the beverage mainly comprises sea-buckthorn fruit juice, raw astragalus root and flavoring agent, wherein the percentage by weight of each constituent are, seabuckthorn fruit juice 0.5-5%, raw astragalus root 0.8-3%, flavoring agent 1-30%, the rest for drinking water. The functional beverage possesses the effect of enhancing human body resistance to diseases, and has good taste.

The invention discloses applications of a P2X3 acceptor conditioning agent benzimidazole compound in preparation of medicines used for treating respiratory diseases. The general formula of the P2X3 acceptor conditioning agent benzimidazole compound is disclosed in the invention. The P2X3 acceptor conditioning agent benzimidazole compound can be used for preparation of medicines used for treating and/or preventing and/or delaying and/or adjuvant therapy of respiratory diseases, is capable of improving COPD damaged pulmonary function obviously, reducing pulmonary artery high pressure obviously,improving lung tissue fibrosis deposition, possesses excellent treatment effect, is high in clinical application value, and is promising in prospect.